Therapeutic targeting of the alpha-secretase pathway to treat Alzheimer's disease.
Copyright policy )Therapeutic targeting of the alpha-secretase pathway to treat Alzheimer's disease.
Alzheimer's disease (AD) is a progressive and degenerative disorder pathophysiologically characterized by the accumulation of beta-amyloid peptides (A-beta) in the brain. A-beta is indicated to be the primary agent in the pathogenesis of AD. A-beta is generated from the amyloid precursor protein (APP) via two proteolytic enzymes, beta- and gamma-secretases. Alpha-secretase conducts an alternative proteolytic cleavage that prevents A-beta production and accumulation. Elevating levels of alpha-secretase cleavage, therefore, is a potential therapeutic strategy to treat AD.
- Drexel University United States
Amyloid beta-Protein Precursor, Amyloid beta-Peptides, Alzheimer Disease, Animals, Humans, Amyloid Precursor Protein Secretases, Models, Biological, Signal Transduction
Amyloid beta-Protein Precursor, Amyloid beta-Peptides, Alzheimer Disease, Animals, Humans, Amyloid Precursor Protein Secretases, Models, Biological, Signal Transduction
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).11 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!